Rubicon Research Limited has announced entering into a definitive agreement to acquire up to 10.5% common stock in Neuronasal, Inc., a clinical-stage pharmaceutical company focused on CNS diseases, for a total consideration of up to USD 2.5 million. The acquisition will be made in tranches through milestone-based share issuance for development activities until March 31, 2027. This minority investment aligns with Rubicon’s strategic expansion in pharmaceutical innovations.​​

The notice reveals that Neuronasal is a pre-revenue stage company based in Wexford, Pennsylvania, USA, incorporated in 2014. It has a net worth of approximately USD 2.75 million as of FY24 and zero turnover, reflecting its current clinical-stage status in developing treatments for central nervous system disorders. The acquisition is not a related-party transaction and requires no regulatory approvals, emphasizing an arm’s length commercial arrangement.​

Rubicon Research Limited is a prominent pharmaceutical company engaged in research, development, manufacturing, and marketing of innovative products globally. Recently, the company successfully completed an IPO in October 2025, raising significant capital for growth and debt repayment. Its global footprint includes US, India, Australia, and Canada, with a robust product pipeline featuring 72 ANDAs and 9 NDAs approved by USFDA. Its most notable branded products include Equetro, Raldesy, and Lopressor OS, with expanding market presence across multiple countries. Rubicon also provides contract manufacturing and has five USFDA inspected R&D facilities.​

In its latest financial results for the quarter ended June 2025, Rubicon Research posted revenue of ₹356.95 crore, a growth of 11% QoQ and 49% YoY. Net profit increased significantly by 69% QoQ and 134% YoY, reaching ₹43.3 crore. For the full fiscal year ending March 31, 2025, Rubicon reported ₹1,296.2 crore in revenue (up 48.6% YoY) and ₹134.36 crore in PAT (up 47.6% YoY), demonstrating strong operational and profitability growth, supported by robust margins and expanding product pipeline. The company has been a favorite among investors for its rapid growth, innovation, and strategic expansion. Popular investor interest was heightened during its highly subscribed IPO in October 2025, which was oversubscribed over 103 times.​

This strategic acquisition of Neuronasal positions Rubicon to deepen its pharmaceutical product pipeline and development capabilities, reinforcing its growth trajectory in 2025 and beyond.

This prepared blog post is formatted for justified font and ready for publication with an engaging, precise, and informative structure covering the notice, company business, recent updates, and latest financial performance.